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Coagulation Status in Women
With Endometriosis
Paola Vigano`, PhD1, Jessica Ottolina, MD2, Veronica Sarais, MD2,
Giorgia Rebonato, PhD2, Edgardo Somigliana, MD3,
and Massimo Candiani, MD2
Abstract
Subtle alterations in coagulation and fibrinolysis have been recently reported in patients with endometriosis supporting a potential
hypercoagulable status associated with the disease. This cross-sectional study aimed at evaluating some variables of coagulation
status and inflammatory markers in women with endometriosis. A total of 314 women who underwent surgery were considered.
The case group (n ¼ 169) included patients with a surgical diagnosis of endometriosis, at any stage of disease. The control group
(n¼ 145) included women with a surgical diagnosis of benign gynecologic pathology. No difference were found for thrombin time,
INR[AQ1], platelet count, neutrophil count, lymphocyte count, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio
(PLR) between women with endometriosis and controls. Conversely, patients with endometriosis had significantly shortened
activated partial thromboplastin time (APTT) when compared to controls (1.08+ 0.06 and 1.12+ 0.19, respectively; P < .01). In
the subgroup analysis, women with ovarian endometriosis had significantly shortened APTT values in comparison to women
without this form and women with stage I to II endometriosis had significantly shorter APTT values and higher PLR than those
with stage III to IV disease. In multivariate logistic regression analysis, after controlling for potential confounders, a shortened
APTT remained associated with the disease. Activated partial thromboplastin time is shorter in women with endometriosis but
still in the normal range. The evidence is insufficient to foresee a possible use of APTT as a diagnostic marker and to claim a crucial
role of a systemic hypercoagulable state in the origin of the disease. A role of the local coagulation system in the pathogenesis of
the disease cannot be excluded.
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Introduction
Recently, increased cardiovascular morbidity in terms of myo-
cardial infarction, angina, and coronary bypass graft interven-
tion has been recognized in women with endometriosis.1,2 The
relative risk of combined coronary heart disease events was
1.62 (95% confidence interval: 1.39-1.89) after adjustment for
confounders.1 Factors contributing to this increased risk have
not been deeply investigated. A portion of this association
could be explained by treatment factors associated with endo-
metriosis such as hormonal therapy and hysterectomy/oophor-
ectomy.3,4 On the other hand, it is worthwhile noting that subtle
alterations in coagulation and fibrinolysis parameters have also
been recently identified in affected patients supporting a poten-
tial hypercoagulable status associated with the disease.5 A sin-
gle contribution has reported that patients with ovarian
endometriomas have significantly shortened activated partial
thromboplastin time (APTT), thrombin time (TT), and elevated
fibrinogen levels, although most of the parameters were in the
normal range. Moreover, the percentage of activated platelets
was shown to be significantly higher in patients with ovarian
endometriotic cysts and to be reduced by their surgical
removal.5 Albeit evidence is controversial, some studies also
documented an increased platelet-to-lymphocyte ratio (PLR) in
women with endometriosis.6-8 Finally, other factors involved in
the coagulation cascade such as tissue factor (TF) and
proteinase-activated receptors have also been reported to be
altered in endometriosis, although their involvement has not
been portrayed in the context of coagulation per se but, rather,
in the context of angiogenesis or inflammation.9,10 Indeed,
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some general inflammatory markers including the
neutrophil-to-lymphocyte ratio (NLR) have been suggested
to be increased in women with endometriosis compared to
controls.6-8,11,12
Normal hemostasis is characterized by a dynamic equili-
brium between procoagulant and anticoagulant components
of the hemostatic system. Therefore, blood hypercoagulability
may be considered as a state of hemostatic imbalance as well as
a shift of the equilibrium toward thrombogenesis occurring
either because of an increase in procoagulant potential or
reduction in antithrombotic capability of the blood.13 If this
imbalance progresses to a critical level, it may lead to onset
of adverse vascular events. It is also important to underlie in
this context that endometriomas are characterized by clotting
factor changes favoring a particular degradative capacity of the
endometrioma fluid that might be supportive of some con-
sumption activity within the cyst.14
In the present cross-sectional study, we aimed at gaining
more insights into the relation between endometriosis and clot-
ting abnormalities. Specifically, we report on levels of coagu-
lation and inflammatory factors in a large series of
reproductive-age women scheduled for gynecological surgery.
Materials and Methods
This cross-sectional study was carried out retrospectively
querying our prospective surgical database at San Raffaele
Scientific Institute in Milan. This database contains clinical,
pathologic, surgical, and follow-up data regarding more than
500 consecutive patients who underwent gynecologic pelvic
surgery. Patients who underwent surgery between January
2013 and December 2015 were considered. All patients had a
surgical indication for gynecologic disease and a histopatholo-
gical diagnosis after either laparotomic or laparoscopic sur-
gery. All participants met the following inclusion criteria:
nonpregnant reproductive-age women, normal hepatic and
renal function tests, and a surgical indication for endometriosis
or other pelvic diseases. Women whose data on the coagulation
status were absent were excluded. All women routinely pro-
vided informed consent for their clinical data and anonymized
records to be used for researches purposes. A specific institu-
tional review board was obtained (End01).
For each patient, age, signs and symptoms, body mass index
(BMI), obstetric and medical history, duration of infertility,
previous in vitro fertilization cycles, smoking status, diameter
of masses, operation type, lateralization, reoperation, surgical
features, and histopathological diagnosis following surgery
were retrieved. A preoperative transvaginal ultrasonographic
examination was performed in all women. The case group
included all patients with a diagnosis of endometriosis, at any
stage of disease. The stage of endometriosis was established
according to the revised classification of the American Society
for Reproductive Medicine.15 Both the surgical and the histo-
pathological examinations confirmed that no stage of endome-
triosis was present in the control group. The control group
included women with a surgical diagnosis of uterine
leiomyomas, tubal pathology, and ovarian benign cysts. Both
case and control patients were excluded if they have taken oral
contraceptives, steroid hormones, antiplatelet drugs, or other
medications in the last 3 months before surgery. Patients were
also excluded if a diagnosis of malignancy was present.
According to the abovementioned selection criteria, 314
women were included, 169 had a diagnosis of endometriosis,
and 145 had a diagnosis of other benign gynecologic diseases.
The routine preoperative included complete blood count
parameters, NLR, PLR, TT ratio, APTT ratio, and INR[AQ2].
Peripheral blood sample of 2 mL was obtained from the med-
ian cubital vein of each patient and mixed with 3.2% citric
acid for anticoagulation purpose. All blood analyses were
obtained at a maximum of 1 month before surgery. The NLR
was obtained by dividing the absolute neutrophil count by the
absolute lymphocyte count, while the PLR was obtained
dividing by the absolute platelets count by the absolute lym-
phocyte count. CA125 and fibrinogen levels were partially
reported in our database, but we established not to include
these variables for the analysis of data incompleteness. All
blood analyses were done during either the follicular or the
luteal phase before surgery.
Statistical analysis was performed using the Statistical Pack-
age for the Social Sciences (SPSS), version Chicago 21.0. The
Shapiro-Wilk test was used to ascertain whether continuous
variables had normal distribution. Continuous and normally
distributed variables were presented as mean + standard
deviation (SD[AQ3]) and intragroup differences were investi-
gated using the student t test. Categorical variables were
expressed as percentages (%), and differences were valuated
using the w2 test. A univariate linear regression analysis was
conducted in order to evaluate the association of each variable
with different phenotypes of endometriosis that were included
in the regression analysis as n1 dummy variables. Regression
coefficients (B) for “ovarian endometriosis” and “peritoneal
endometriosis” represent the difference in the mean values
compared to the reference category “deep endometriosis” that
was indicated by B ¼0. Multivariate analyses were performed
using logistic regression analyses in order to determine inde-
pendent predictors of endometriosis disease. P values of <.05
were considered statistically significant.
The sample size was calculated focusing on APTT as the
primary outcome. The expected mean + SD of this variable
in the control group was 1.0+ 0.1. Setting type I and II errors
at 0.05 and 0.10, respectively, and stating as clinically rele-
vant a 5% difference, the required sample size was at least 85
women per group. The available database could well satisfy
this estimated sample size. We did not stop recruitment at the
precise scheduled sample size to allow for more robust sub-
group analyses.
Results
Baseline characteristics of patients with and without endome-
triosis are shown in Table 1. Of the 169 affected women, 45
were stages I to II, whereas the remaining 124 were stages III to
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IV. The concomitant presence of other gynecological benign
pathologies was observed in 44 (26%) cases and were as fol-
lows: ovarian dermoids (n ¼ 4), seromucinous ovarian cysts
(n ¼ 7), tubal pathology (n ¼ 21), and myomas (n ¼ 12).
Endometriosis could not be detected in 145 women. These
cases were used as controls. The main diagnoses of this group
were as follows: ovarian dermoids (n ¼ 13), tubal pathology
(n ¼ 37), seromucinous ovarian cysts (n ¼ 21), paraovarian
cysts (n¼ 8), and myomas (n¼ 54), and normal pelvis (n¼ 12).
As previously reported,16,17 the concentration of none of the
molecules tested appears to be influenced by the phase of the
cycle. In proliferative and secretory phase controls, TT ratio
was 1.00 + 0.9 and 0.970 + 0.10, INR was 0.99 + 056 and
0.98 + 0.16, APTT ratio was 1.12 + 0.19 and 1.13 + 0.15,
platelet count was 262.20+ 55.8 109/L and 1.13+ 63.4 109/L,
neutrophil count was 3.76+ 1.34 109/L and 4.31+ 1.89 109/L,
lymphocyte count was 2.04 + 0.56 109/L and 1.87 + 0.52
109/L, respectively.
We found no difference in TT (P ¼ .74), INR (P ¼ .87),
platelet count (P ¼ .63), neutrophil count (P ¼ .78), lympho-
cyte count (P ¼ .78), NLR (P ¼ .94), and PLR (P ¼ .76)
between women with endometriosis and controls. Conversely,
we found that patients with endometriosis had significantly
shortened APTT when compared to controls (P ¼ .04;
Figure 1). This difference was maintained in both phases of
the menstrual cycles. In proliferative phase, APTT was 1.12+
0.19 and 1.08 + 0.06 (P ¼ .01), respectively, in controls and
patients with endometriosis, while in the secretory phase, it was
1.13 + 0.15 and 1.08 + 0.06 (P ¼ .05), respectively. No
differences were observed in coagulation parameters among
subgroups of controls (ovarian dermoids, tubal pathology,
seromucinous ovarian cysts, and myomas).
When we considered the various manifestations of endome-
triosis separately (Table 2), we found that women with ovarian
disease had shortened APTT values (P ¼ .04) in comparison to
women without this form (controls and women with peritoneal
and deep endometriosis); moreover, a significant between-
group difference emerged in NLR, as women with peritoneal
lesions had lower NLR if compared to patients without this
form (P ¼ .01). In addition, women with stage I to II endome-
triosis had slightly shorter APTT values and higher PLR than
those with stage III to IV disease, and the differences reached
statistical significance (P ¼ .01 and P ¼ .005, respectively). If
compared to controls, women with stage III to IV had statistical
significantly shorter APTT values as well (P ¼ .04, data
not shown).
In multivariate logistic regression analysis, after controlling
for potential confounders (age, parity, BMI, and smoking),
APTT retained significant predictive value for endometriosis
disease (P ¼ .04; Table 3).
Discussion
In this study, we failed to document an important relation
between endometriosis and the peripheral coagulation system.
A statistically significant shortening of the APTT emerged in
women with endometriosis, but the magnitude of the difference
was modest. Moreover, in the subanalysis according to the
various forms of the disease, a shortened APTT was found to
be associated with the presence of ovarian cysts only. This
result is in line with previous evidence by Wu et al who indeed
demonstrated a shorten APTT in women with ovarian endome-
triosis.5 On the other hand, we could not confirm alterations in
other coagulation variables such as TT which were previously
claimed to be altered in affected women.
Importantly, although patients with endometriosis had sig-
nificantly shortened APTT when compared to controls, these
concentrations remain in the normal range and this of course
poses some doubts about the clinical relevance of this finding.
Moreover, although in multivariate logistic regression analysis
APTT retained significant predictive value for endometriosis
disease, given the small difference detected, a diagnostic use-
fulness of this parameter is unlikely.
A short APTT can be used as a surrogate marker for elevated
levels of coagulation factors (except factor VII) and seems
suitable to reflect any hemostatic balance in favor of a pro-
thrombonic state. The underlying mechanism for increased
thrombonic risk with shortened APTT has not been completely
elucidated, but it is known that a short APTT is associated with
hemostatic activation as evidenced by elevations in prothrom-
bin fragment 1,2, thrombin–antithrombin complexes, D-dimers,
and factor VIII coagulant activity, all markers for increased
thrombin generation in plasma.18 The reason for the observed
alteration in APTT in women with endometriosis without the
involvement of any other coagulation factor is unknown.
Endometriosis is characterized by a sterile, local inflamma-
tion occurring in the peritoneal cavity of women affected and
an altered function of immune-related cells occurs in the peri-
toneal environment.19 Moreover, based on studies at the sys-
temic level, the disease can be recognized as a local affliction
with relevant consequences also systemically.19-23 Indeed, it
induces the expression of genes in peripheral leukocytes
already identified in nongynecologic chronic inflammatory dis-
eases. In this regard, there is an increasing evidence that an
extensive cross-talk between the systems of coagulation and
inflammation exists, whereby inflammation leads to activation
of coagulation and coagulation also markedly affects inflam-
matory activity.24 Tissue factor plays a central role in the
Table 1. Baseline Characteristics of Controls and Patients With
Endometriosis.
Characteristics Endometriosis Controls P
Number of patients 169 145
Age, years 35.8+ 5.9 36.9+ 6.5 .4
BMI, kg/mq 22.8+ 3.3 22.9+ 3.6 .5
Smoking 25.6% 17.7% .08
Previous delivery 18.3% 27.1% .055
Infertility 14.5% 13.9% .6
Cycle phase: proliferative;
secretory
56.8%; 43.2% 53.1%; 46.9% .7
Abbreviation: BMI, body mass index.
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Figure 1. Boxplots of levels of coagulation parameters (A: TT, B: APTT, C: INR; D: Plateler count; H: platelet/lymphocyte ratio) and systemic
inflammatory response markers (E: neutrophil count; F: lymphocyte count; G: neutrophil/lymphocyte ratio) in patients with endometriosis and
controls (*P < .05 vs controls). APTT indicates activated partial thromboplastin time; TT, thrombin time[AQ4].
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initiation of inflammation-induced coagulation,25 since, on
exposure to blood, it starts a reaction cascade that culminates
in the generation of thrombin. Since endometriotic cells
express TF,9 we cannot exclude that the alteration demon-
strated herein represents the subtle manifestation of the activa-
tion of the TF pathway at the level of endometriotic lesions.
Differences among studies in coagulation parameters might
thus be related to disease variability among patients. In other
words, the weak and clinically debatable evidence emerging
from our study tends to rule out a role of the coagulation system
in the origin of the disease. Endometriosis would not develop
more commonly in women with a shorter APTT. On the other
hand, our data cannot be used to deny a relevant role of the
coagulation system in the pathogenesis of endometriosis. The
mild variations captured at the peripheral levels may reflect a
more relevant local alteration. Perturbation of the coagulation
system may occur at some time during the pathogenetic process
and may have a crucial role in the establishment or progression
of the disease.
In this regard, it is noteworthy that women with a more
severe disease do not seem to have a shorter APTT, and the
alteration seems to be associated with the presence of the endo-
metriotic cyst. In this context, it should be considered that an
endometrioma contains free iron, reactive oxygen species, pro-
teolytic enzymes, and inflammatory molecules in concentra-
tions from tens to hundreds of times higher than those
present in peripheral blood or in other types of benign
cysts.14,26 Concentrations of some coagulation parameters such
as plasminogen activator inhibitor-1 (PAI-1), PAI-2, and uro-
kinase plasminogen activator were found to be in the same
range or even much higher in the endometrioma fluid com-
pared to malignant tumors, and it is reasonable to think that
this content may leak from the cyst and be absorbed through
the peritoneal surface. Similar to what happens in slowly
evolving disseminated intravascular coagulation (DIC),
APTT values may actually become shorter than normal in
plasma, probably because of the increased presence of acti-
vated coagulation factors in the plasma (Guidelines for the
diagnosis and management of disseminated intravascular coa-
gulationD 2009).27 The large amounts of coagulation-related
products present in the endometrioma is evident in case of
cyst rupture that can cause the rapid elevation in plasma D
dimer to levels higher than those reported in cases of acute
leukemia or with a major embolism.28,29
We have also found a significantly lower NLR in women
with peritoneal lesions compared to patients without this form.
Again, the magnitude of the difference observed is however
small, and we have serious concerns about any clinical signifi-
cance. Data in the literature on NLR in endometriosis are
inconsistent with some contributions reporting higher levels
in women affected and others reporting no difference.6 Finally,
although the platelet count was similar between patients with
endometriosis and controls and in the various subanalyses, PLR
Table 2. Coagulation Parameters and Systemic Inflammatory Response Markers According to the Presence of the Different Forms of
Endometriosis[AQ5].
Diagnosis TT (Ratio) APTT (Ratio) INR P, 109/L N, 109/L L, 109/L NLR PLR
Endometrioma
Present (n ¼ 98) 0.99+ 0.06 1.08+ 0.07 0.99+ 0.71 254.5+ 61.47 3.9+ 1.62 2.02+ 0.66 2.08+ 1.01 135.18+ 68.69
Absent (n ¼ 145) 0.99+ 0.09 1.14+ 0.07 0.99+ 0.11 254.7+ 58.62 3.99+ 1.6 1.97+ 0.55 2.16+ 1.25 130.65+ 52.8
P .901 .040 .741 .637 .245 .691 .522 .209
Peritoneal endometriosis
Present (n ¼ 58) 1.00+ 0.06 1.07+ 0.06 1.00+ 0.06 257.9+ 62.8 3.98+ 1.64 2.01+ 0.54 2.10+ 0.98 137.27+ 77.68
Absent (n ¼ 145) 0.99+ 0.09 1.14+ 0.07 0.99+ 0.11 254.7+ 58.62 3.99+ 1.6 1.97+ 0.55 2.16+ 1.25 130.65+ 52.8
P .641 .068 .108 .364 .493 .965 .019 .319
Deep endometriosis
Present (n ¼ 69) 0.99+ 0.06 1.06+ 0.11 0.99+ 0.11 248.02+ 48.23 3.96+ 1.88 2.04 + 0.62 2.17+ 1.68 130.8+ 49.87
Absent (n ¼ 145) 0.99+ 0.09 1.14+ 0.07 0.99+ 0.11 254.7+ 58.62 3.99+ 1.6 1.97+ 0.55 2.16+ 1.25 130.65+ 52.8
P .954 .099 .719 .581 .251 .711 .757 .943
Endometriosis (all forms)
Stage I-II (n ¼ 45) 1.00+ 0.08 1.05+ 0.15 1.01+ 0.07 253.21+ 72.75 4.01+ 1.74 1.91+ 0.56 2.43+ 2.19 153.09+ 90.92
Stage III-IV (n ¼ 124) 0.99+ 0.06 1.07+ 0.07 0.99+ 0.07 250.59+ 55.01 4.05+ 1.67 2.07+ 0.66 2.08+ 0.95 129.57+ 42.6
P .228 .012 .590 .538 .202 .538 .213 .005
Abbreviations: APTT, activated partial thromboplastin time; L, lymphocyte count; N, neutrophil count; N/L, neutrophil/lymphocyte ratio; NLR, neutrophil-to-
lymphocyte ratio; P, platelet count; P/L, platelet/lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; TT, thrombin time.
Table 3. Multivariate Logistic Regression of Variables Predicting
Endometriosis Disease.
Variable B coefficient SE OR P
TT (ratio) 0.166 14.08 .991
APTT (ratio) 1.31 1.07 0.267 .042
INR 1.683 10.92 .878
Platelets (109/L) 0.005 0.005 .345
Neutrophils (109/L) 0.039 0.228 .863
Lymphocytes (109/L) 0.418 0.533 .433
Neutrophil/lymphocyte ratio 0.108 0.368 .768
Platelet/lymphocyte ratio 0.007 0.008 .406
Abbreviations: APTT, activated partial thromboplastin time; TT, thrombin
time.
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resulted significantly reduced in patients with stages III to IV
endometriosis than in those with stage II to III disease. Two
studies have addressed the relationship between PLR and
endometriosis, one reporting increased and the other
similar levels of PLR between women with and without
endometriosis.7,8 Severe forms resulted to have even higher
levels in 1 report and similar levels in the other. The great
variability in endometriosis manifestations and forms is
likely to explain all these inconsistencies.
This study has some limitations: (1) the retrospective
design of the study that could have influenced the interpreta-
tion of our findings and (2) the presence of only 1 type of
controls, the surgical population. For these reasons, the results
should be taken with caution. On the other hand, all the parti-
cipants considered had a laparoscopic diagnosis, were not on
oral contraceptives, and we could include a large sample size
with a great variety of forms and manifestations of the dis-
ease. Moreover, a consistent number of coagulation variables
have been evaluated.
In summary, we confirm the presence of a shorter, but still in
the normal range, APTT in women with ovarian endometrio-
mas compared to a control population. The evidence is insuffi-
cient to foresee a possible use of APTT as a diagnostic marker
and to claim a crucial role of a systemic hypercoagulable state
in the origin of the disease. However, our evidence does not
exclude a role of the local coagulation system in the pathogen-
esis and progression of endometriosis. Further evidence is
required to investigate this possibility, possibly evaluating
more coagulation parameters or inflammatory markers.
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